SAN DIEGO–IQHQ, Inc., a premier life sciences real estate development company, announced key additions to its Board of Directors – naming Janice Sears and Anshul Mangal as independent directors.
With decades of relevant life science and commercial real estate experience, Sears and Mangal join IQHQ at a critical juncture as the company builds out its development portfolio in San Francisco, San Diego, Boston, and the United Kingdom.
“We are pleased to add Janice and Anshul to our esteemed Board of Directors,” said Steve Rosetta, CEO of IQHQ. “Janice brings an unparalleled track record of financial, investor, and commercial real estate expertise, which will play a critical role in our future growth plans. Anshul is a biotech entrepreneur, experienced executive, philanthropist, and attorney, who will inform our work to develop innovative districts that meet the needs of leading life science companies while attracting top talent.”
Sears is the Retired President of the San Francisco market of Bank of America. During her accomplished career at Bank of America, she also served as the West Coast Region Head for Real Estate Investment Banking, and the West Coast Region Head for Commercial Real Estate. Prior to joining Bank of America, she held prominent positions at Chemical Bank and Citigroup in New York City. Sears has served on numerous Boards, including current director roles for Sonder Holdings Inc. (NASDAQ: SOND) and Invitation Homes (NYSE: INVH). She holds a Bachelor of Science in Economics and Marketing from the University of Delaware.
“I am pleased and honored to be joining the Board of Directors at IQHQ and to work with a seasoned and talented management team, as well as a group of sophisticated life sciences investors,” said Sears. “The pandemic has shown everyone the importance of this sector and IQHQ is extraordinarily well positioned to help the sector grow and thrive in key innovation markets.”
Mangal brings a wide range of entrepreneurial, management, and philanthropic experience to the Board. He currently serves as the founder and president of Project Farma (PF), a premier worldwide biologics and advanced therapy engineering consulting firm and Precision ADVANCE, Precision Medicine Group’s cell and gene collective. Mangal is also the Chief Strategy Officer for The Institute for Life Changing Medicines, a nonprofit organization that identifies, develops, and promotes access to life-changing medicines for diseases not considered commercially viable. Prior to PF, Mangal was a patent litigator at Jones Day and a pro bono attorney who helped refugees secure asylum in the United States. He earned a Bachelor of Science degree in Computer and Electrical Engineering from Purdue University and his Juris Doctor from the John Marshall Law School (now the University of Illinois Chicago School of Law).
“I am excited to join the IQHQ Board of Directors and use my expertise to further the development of IQHQ’s portfolio,” said Mangal. “I have been fortunate to work closely with life science leaders to improve the lives of patients, and am excited to further that work by helping these leaders have a place for their innovation to flourish via IQHQ.”